Hetero launches Sofovir (Sofosbuvir) in India

India, Hyderabad, 7th April 2015: Hyderabad-based pharmaceutical company Hetero Drugs have received the approval from the Drugs Controller General (India) to sell generic versions of sofosbuvir tablets (400 mg) in India.

Sofosbuvir is a blockbuster drug to treat chronic hepatitis C infection and is sold globally by US pharmaceutical major Gilead Sciences under its brand Sovaldi. Gilead recently entered into nonexclusive licensing agreements with the two companies and six other Indian generic pharmaceutical manufacturers to make generic versions of the drug.

Hetero Drugs is launching it under the brand Sofovir, Hetero will be selling to all 91 countries over the next 6-9 months, Hetero have to register in each market after India and will start with the ASEAN countries and then go to other markets

About Hetero

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Established by Dr. B.P.S. Reddy in 1993, Hetero is in the business of development, manufacturing and marketing of drug intermediates, active pharmaceutical ingredients (APIs), and finished dosages.

Hetero has over 25 state-of-the-art manufacturing facilities which has been approved by various regulatory authorities like US FDA, EU, TGA – Australia, MCC – South Africa among others. With more than 200 products in its portfolio across various therapeutic areas, Hetero has a strong global presence in 120+ countries. The company focuses on making affordable medicines accessible to patients worldwide. For more information on Hetero, please visit www.heteroworld.com.

Media Contact:

Jeyasingh Balakrishnan
Head – Corporate Communications
Hetero Labs Limited, India
Mobile: +91 9989626541/ +91 9833836185
Email: Jeyasingh.b@heterodrugs.com